(1) Background: The WiZen study is the largest study so far to analyze the effect of the certification of designated cancer centers on survival in Germany. This certification program is provided by the German Cancer Society (GCS) and represents one of the largest oncologic certification programs worldwide. Currently, about 50% of colorectal cancer patients in Germany are treated in certified centers. (2) Methods: All analyses are based on population-based clinical cancer registry data of 47.440 colorectal cancer (ICD-10-GM C18/C20) patients treated between 2009 and 2017. The primary outcome was 5-year overall survival (OAS) after treatment at certified cancer centers compared to treatment at other hospitals; the secondary endpoint was recurrence-free survival. Statistical methods included Kaplan–Meier analysis and multivariable Cox regression. (3) Results: Treatment at certified hospitals was associated with significant advantages concerning 5-year overall survival (HR 0.92, 95% CI 0.89, 0.96, adjusted for a broad range of confounders) for colon cancer patients. Concentrating on UICC stage I–III patients, for whom curative treatment is possible, the survival benefit was even larger (colon cancer: HR 0.89, 95% CI 0.84, 0.94; rectum cancer: HR 0.91, 95% CI 0.84, 0.97). (4) Conclusions: These results encourage future efforts for further implementation of the certification program. Patients with colorectal cancer should preferably be directed to certified centers.
(1) 背景：WiZen研究是目前德国规模最大的、旨在分析指定癌症中心认证对患者生存影响的研究。该认证项目由德国癌症协会提供，是全球规模最大的肿瘤认证体系之一。目前德国约50%的结直肠癌患者在认证中心接受治疗。(2) 方法：所有分析基于2009年至2017年间47,440例结直肠癌（ICD-10-GM C18/C20）患者的基于人群的临床癌症登记数据。主要结局指标为认证癌症中心与其他医院治疗后5年总生存期比较；次要终点为无复发生存期。统计方法包括Kaplan-Meier分析和多变量Cox回归。(3) 结果：认证医院治疗与结肠癌患者5年总生存期显著优势相关（HR 0.92，95% CI 0.89-0.96，经广泛混杂因素调整）。聚焦可能接受根治性治疗的UICC I-III期患者，生存获益更为显著（结肠癌：HR 0.89，95% CI 0.84-0.94；直肠癌：HR 0.91，95% CI 0.84-0.97）。(4) 结论：研究结果支持未来进一步推进认证项目的实施。结直肠癌患者应优先引导至认证中心接受治疗。
肿瘤(癌症)患者之家